BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

N30 Pharma Announces Financing and Addition to Board


5/12/2010 9:10:57 AM

BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors.

Joining the Company's Board of Directors will be Dr. Howard Furst of Deerfield Management.

"I am pleased with this successful financing. It will provide resources to move our first drug, N6022 into human testing, as well as support the development of other novel new drugs from our discovery and development platform. In addition, Dr. Furst brings a wealth of healthcare investment and medical expertise to our Board," commented Charles Scoggin MD, CEO of N30.

About N30 Pharma N30 Pharma is a clinical-stage company developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. N30 drugs target s-nitrosoglutathione reductase (GSNOR), the only druggable enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO, and other SNO's are important modulators of inflammation as well as airway and vascular smooth muscle. N30 is a privately held company headquartered in Boulder, Colorado.

SOURCE N30 Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES